Furthermore, if the CCK-BR-targeted NP can also deliver gastrin siRNA [24] or other payloads to the PanIN lesions such as siRNA for mutant KRAS, these NPs would have the potential not only to identify but also to also treat these PanIN lesions to decrease proliferation and halt the progression to cancer. The gene discussed is CCKBR; the disease is cancer.